Other factors, including the levels of ‘free’ RXRα that is available for PPARγ-RXRα interaction, the content of other nuclear receptors, and the possible interaction among nuclear coactivators and corepressors, may play an important role in determining the sensitivity of cancer cells to the nuclear receptor agonists (Torchia et al, 1998). The gene discussed is RXRA; the disease is cancer.